SCHEDULE 13G/A: Vanguard Group Discloses 7.14% Passive Stake in Relay Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting a 7.14% beneficial ownership stake in Relay Therapeutics Inc., held for ordinary course investment purposes.

Summary

• The Vanguard Group, based in Malvern, PA, has filed an Amendment No. 3 to its Schedule 13G regarding its beneficial ownership in Relay Therapeutics Inc.
• As of March 31, 2025, The Vanguard Group beneficially owns an aggregate of 12,105,420 shares of Relay Therapeutics Inc. Common Stock.
• This ownership represents 7.14% of the class of securities.
• Vanguard holds sole voting power over 0 shares, shared voting power over 83,258 shares, sole dispositive power over 11,913,273 shares, and shared dispositive power over 192,147 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Relay Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance data that would indicate a strong positive or negative sentiment. It is neutral in tone and purpose.

Positives

• The presence of a major institutional investor like The Vanguard Group holding a significant 7.14% stake can be viewed as a positive signal of institutional confidence or inclusion in major index funds for Relay Therapeutics Inc.

Negatives

• The Schedule 13G filing itself does not contain negative information about Relay Therapeutics Inc.
• The passive nature of Vanguard's investment, as indicated by the 13G filing, means they are not seeking to influence control or engage in activist interventions, which might be a 'negative' for shareholders seeking such involvement.

Risks

• The document, being a Schedule 13G, primarily details beneficial ownership and does not disclose specific operational, financial, or strategic risks related to Relay Therapeutics Inc.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer, which means Vanguard will not be actively involved in corporate governance or strategic decisions beyond their passive investment.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Relay Therapeutics Inc.'s future performance or strategic outlook. It is solely a disclosure of beneficial ownership by The Vanguard Group.

Management Comments

• Ashley Grim, Head of Global Fund Administration for The Vanguard Group, certified that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing reflects a routine disclosure by a major asset manager, The Vanguard Group, regarding its passive investment in a biotechnology company, Relay Therapeutics Inc. Such institutional holdings are common across the biotech and pharmaceutical sectors, indicating inclusion in broad market or sector-specific index funds and managed portfolios.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional presence in Relay Therapeutics Inc.'s stock, which may provide a degree of stability or liquidity. However, it also indicates that this large holder is passive and not seeking to influence management or strategy.
• Investment Professionals: Provides updated information on institutional ownership, which is a key data point for market analysis and understanding the shareholder base.

Key Dates

Keywords

Relay Therapeutics Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment, Biotechnology, Pharmaceuticals